MEDICAL CHRONICLE DECEMBER 2018 CPD 3 of 3: Recently the DECLARE trial was published evaluating in a randomised, double-blind, multinational, placebo- controlled trial, the effect of Dapagliflozin on safety and efficacy for macrovascular and microvascular outcomes.

The sodium-glucose cotransporter 2 inhibitors are a new class of drugs for the treatment of diabetes type 2

Please sign in to read more